GeoVax Labs, Inc. Q3 FY2023 earnings call

• Strategy: GeoVax's strategy is to innovate, differentiate, accelerate, and collaborate, focusing on cancer therapies and infectious disease vaccines. - Gedeptin: A therapy for advanced head and neck cancer using GDEPT technology, with Phase 1 data showing tolerance and tumor size reduction. - GEO-CM04S1: Next-generation COVID-19 vaccine targeting immune-compromised individuals, with interest in Project NextGen. - GEO-MVA: Vaccine against Mpox and smallpox, aiming to disrupt the existing monopoly. - Participation: Engaging in oncology conferences to present Gedeptin data and seek partnerships. - Priorities: Advancing Phase 2 clinical programs for Gedeptin and CMO4S1, and MVA vaccine registration.

Research and development expenses for the three-month period in 2023 were $6.9 million and $14.5 million for the nine-month period, compared to $2.7 million and $5.4 million in 2022, primarily driven by clinical trial activity for CMO4S1 and Gedeptin programs. General and administrative expenses were $1.7 million for the three-month period and $4.6 million for the nine-month period in 2023 versus $1.2 million and $3.4 million in 2022. Net loss for the nine-month period of 2023 was approximately $18 million, or $0.69 per share, compared to $8.6 million in 2022, $0.63 per share. Cash balances at September 30, 2023, were approximately $12.7 million, down from $27.6 million at the end of 2022.

• 2024: Report final results from Gedeptin's current trial and plans for an expanded Phase 2 trial. - CMO4S1: Report results from Healthy Volunteer Booster trial, Immunocompromised DLL trial, and Immunocompromised Stem Cell Transplant trial. - MVA vaccine: Progress on registration and advanced manufacturing process.

• Uncertainty in developing and manufacturing product candidates. - Regulatory approval challenges. - Difficulty in raising required capital. - Competition from other products. - Ability to enter favorable manufacturing and distribution agreements, as detailed in GeoVax's SEC filings.

Q: There have been a tremendous number of COVID reinfections. People who had COVID recovered from it, and now they are getting it again. I noticed that the emergency use authorization is now approved for Pfizer's Paxlovid. And Paxlovid is getting prescribed quite a lot. I'm just wondering how this impacts the marketplace and does it impact immune compromised patients at all?

A: David Dodd stated that immunocompromised patients aren't responding well to Paxlovid, and there's still a need for GeoVax's vaccine. Kelly McKee added that Paxlovid is a therapeutic, not a vaccine, and their vaccine can prevent illness better. David Dodd also mentioned that data from the CMO4S1 healthy volunteer booster trial may show the vaccine's breadth and durability.